ArticleMaterials today. Bio2026
Bioinspired lipid droplets nanoplatform for periodontitis therapy: Integrated antibacterial, mitochondrial repair, and immunomodulatory functions.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Application of injectable hydrogels in the treatment of periodontitis.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Periodontitis, a multifactorial inflammatory disease driven by microbial dysbiosis, dysregulated immunity, and oxidative stress, demands therapeutic strategies that concurrently address interconnected pathological pathways. Here, a biomimetic lipid droplet-based nanoplatform (GA@LDs-CRAMP) is engineered to achieve spatiotemporal coordination of antibacterial, antioxidant, and immunomodulatory functions for the treatment of periodontitis. Constructed using RAW264.7 macrophage-derived lipid droplets (LDs), the GA@LDs-CRAMP system anchors cathelicidin-related antimicrobial peptide (CRAMP) onto LDs surfaces via lipopolysaccharide (LPS)-stimulated recruitment, while encapsulating gambogic acid (GA) within its hydrophobic core for mitochondria-targeted delivery. The nanoplatform demonstrates comprehensive therapeutic efficacy against periodontitis by suppressing periodontopathogen proliferation, restoring oxidative stress-damaged mitochondria through reactive oxygen species (ROS) scavenging, inhibiting inflammatory cascades via nuclear factor erythroid 2-related factor 2 (Nrf2)/nuclear factor-kappa B (NF-κB)-mediated antioxidant signaling activation, and reprogramming macrophage polarization from pro-inflammatory M1 to tissue-reparative M2 phenotypes. In preclinical periodontitis models, localized delivery of GA@LDs-CRAMP effectively mitigates inflammatory cytokine storms and attenuates alveolar bone resorption. Collectively, this study demonstrates the potential of leveraging lipid droplets organelles to engineer precision-targeted, multifunctional drug delivery systems for periodontitis therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.